Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytrx Corporation (CYTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,752
  • Shares Outstanding, K 27,640
  • Annual Sales, $ 200 K
  • Annual Income, $ -50,770 K
  • 36-Month Beta 2.27
  • Price/Sales 375.55
  • Price/Cash Flow N/A
  • Price/Book 2.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.67 +5.39%
on 12/28/17
1.92 -8.33%
on 01/04/18
+0.02 (+1.15%)
since 12/19/17
3-Month
1.65 +6.67%
on 12/19/17
2.59 -32.05%
on 11/01/17
-0.40 (-18.52%)
since 10/19/17
52-Week
1.65 +6.67%
on 12/19/17
6.00 -70.67%
on 07/31/17
-0.76 (-30.16%)
since 01/19/17

Most Recent Stories

More News
CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks,...

CYTR : 1.76 (-2.22%)
CytRx Corporation to Present at Biotech Showcase 2018

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President...

CYTR : 1.76 (-2.22%)
CytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its presentation scheduled to be delivered at the LD Micro 10th Annual...

CYTR : 1.76 (-2.22%)
CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR(TM) Drug Candidates

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has filed provisional patent applications covering two series of...

CYTR : 1.76 (-2.22%)
CytRx Corporation to Present at Upcoming Investor Conferences

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO, Steven A. Kriegsman, will present at the LD Micro...

CYTR : 1.76 (-2.22%)
Today's Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx Corporation

NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Eleven Biotherapeutics shares moved higher on Friday as investors continued to cheer the company's update last week in its earnings call about its Vicinium...

EBIO : 0.82 (+1.23%)
CYTR : 1.76 (-2.22%)
CytRx Corporation Regains Nasdaq Listing Compliance

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it received written notification on November 16, 2017, from the NASDAQ...

CYTR : 1.76 (-2.22%)
CytRx Reports Third Quarter 2017 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ended September 30, 2017, and provided...

CYTR : 1.76 (-2.22%)
CytRx Announces Strategic Realignment of Clinical Development Team

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the strategic realignment of its drug development efforts for advancing...

CYTR : 1.76 (-2.22%)
CytRx Corporation Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted recent progress achieved by its discovery laboratory with its innovative...

CYTR : 1.76 (-2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

See More

Key Turning Points

2nd Resistance Point 1.82
1st Resistance Point 1.79
Last Price 1.76
1st Support Level 1.74
2nd Support Level 1.72

See More

52-Week High 6.00
Fibonacci 61.8% 4.34
Fibonacci 50% 3.83
Fibonacci 38.2% 3.31
Last Price 1.76
52-Week Low 1.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.